The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
CymaBay Therapeutics Common Stock 23257D103 1,261 650,000 SH   SOLE   650,000 0 0
Dicerna Pharmaceuticals Common Stock 253031108 1,835 223,457 SH   SOLE   223,457 0 0
Egalet Common Stock 28226B104 34,868 2,645,558 SH   SOLE   2,645,558 0 0
ESSA Pharma Common Stock 29668H104 6,884 1,090,909 SH   SOLE   1,090,909 0 0
FibroGen Common Stock 31572Q808 19,118 872,175 SH   SOLE   872,175 0 0
Juno Therapeutics Common Stock 48205A109 54,098 1,329,512 SH   SOLE   1,329,512 0 0
Nabriva Therapeutics Sponsored ADR 62957M104 10,886 1,145,890 SH   SOLE   1,145,890 0 0
Paratek Pharmaceuticals Common Stock 699374302 40,639 2,138,872 SH   SOLE   2,138,872 0 0
Pieris Pharmaceuticals Common Stock 720795103 4,546 2,483,949 SH   SOLE   2,483,949 0 0
Proteon Therapeutics Common Stock 74371L109 3,478 250,000 SH   SOLE   250,000 0 0